Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Medtronic
McKinsey
AstraZeneca
Colorcon

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Dupilumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Dupilumab: Patents, clinical trial progress, indications

Dupilumab is an investigational drug.

There have been 54 clinical trials for Dupilumab. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2019.

The most common disease conditions in clinical trials are Dermatitis, Eczema, and Dermatitis, Atopic. The leading clinical trial sponsors are Regeneron Pharmaceuticals, Sanofi, and University of California, San Francisco.

There are eleven US patents protecting this investigational drug and one hundred and six international patents.

Recent Clinical Trials for Dupilumab
TitleSponsorPhase
Dupilumab in Eosinophilic GastritisRegeneron PharmaceuticalsPhase 2
Dupilumab in Eosinophilic GastritisChildren's Hospital Medical Center, CincinnatiPhase 2
Clinical Study Using Biologics to Improve Multi OIT OutcomesStanford UniversityPhase 2

See all Dupilumab clinical trials

Clinical Trial Summary for Dupilumab

Top disease conditions for Dupilumab
Top clinical trial sponsors for Dupilumab

See all Dupilumab clinical trials

US Patents for Dupilumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Dupilumab   Start Trial Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders Knopp Biosciences LLC (Pittsburgh, PA)   Start Trial
Dupilumab   Start Trial Methods for treating nasal polyposis by administering an IL-4R antagonist SANOFI BIOTECHNOLOGY (Paris, FR) REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY)   Start Trial
Dupilumab   Start Trial Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist SANOFI BIOTECHNOLOGY (Paris, FR) REGENERON PHARMACEUTICALS, INC (Tarrytown, NY)   Start Trial
Dupilumab   Start Trial Methods for treating or preventing asthma by administering an IL-4R antagonist Sanofi Biotechnology (FR) Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Dupilumab

Drugname Country Document Number Estimated Expiration Related US Patent
Dupilumab Australia 2014287067 2033-07-12   Start Trial
Dupilumab Australia 2014306597 2033-07-12   Start Trial
Dupilumab Australia 2014306683 2033-07-12   Start Trial
Dupilumab Australia 2017276231 2033-07-12   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.